November 02, 2023 (Earnings Report) Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
Seelos Therapeutics
Symbol: SEEL
Recent Price: $0.18
Average Analyst Price Target: $2.50 (1258.70%)
Market Cap: $27.33M
Last Year's EPS: -0.12
Consensus EPS Forecast: -0.09
Expected Earnings Date: 2023-09-29
Recent Analyst Action: Yatin Suneja, analyst at Guggenheim, reiterates coverage on Seelos Therapeutics (SEEL) in the Healthcare sector with a Hold rating and a price target of n/a (1 month ago).
TipRanks.com also reports that Seelos Therapeutics currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $2.50 . The target pricing ranges from a high forecast of $4 down to a low forecast of $1. Seelos Therapeutics (SEEL)’s last closing price was $0.18 which would put the average price target at 1258.70% upside.Here are 3rd party ratings for SEEL:
Recent Analyst Action: Daniel Fannon, analyst at Jefferies, reiterates coverage on Icahn Enterprises (IEP) in the Industrials sector with a Buy rating and a price target of $27 (2 months ago).
TipRanks.com also reports that Icahn Enterprises currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $27.00 . The target pricing ranges from a high forecast of $27 down to a low forecast of $27. Icahn Enterprises (IEP)’s last closing price was $16.36 which would put the average price target at 65.04% upside.Here are 3rd party ratings for IEP:
Recent Analyst Action: Jeffrey Garro, analyst at Stephens, reiterates coverage on Privia Health Group (PRVA) in the Healthcare sector with a Buy rating and a price target of $27 (3 days ago).
TipRanks.com also reports that Privia Health Group currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $30.10 . The target pricing ranges from a high forecast of $36 down to a low forecast of $26. Privia Health Group (PRVA)’s last closing price was $20.42 which would put the average price target at 65.28% upside.Here are 3rd party ratings for PRVA:
Recent Analyst Action: Andrew Kuske, analyst at Credit Suisse, reiterates coverage on Brookfield Business Partners (BBU) in the Real Estate sector with a Buy rating and a price target of $26 (2 months ago).
TipRanks.com also reports that Brookfield Business Partners currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $27.00 . The target pricing ranges from a high forecast of $35 down to a low forecast of $18. Brookfield Business Partners (BBU)’s last closing price was $13.14 which would put the average price target at 97.91% upside.Here are 3rd party ratings for BBU:
Recent Analyst Action: Charles Neivert, analyst at Piper Sandler, reiterates coverage on AdvanSix (ASIX) in the Basic Materials sector with a Buy rating and a price target of $40 (3 weeks ago).
TipRanks.com also reports that AdvanSix currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $47.00 . The target pricing ranges from a high forecast of $57 down to a low forecast of $40. AdvanSix (ASIX)’s last closing price was $27.23 which would put the average price target at 72.60% upside.Here are 3rd party ratings for ASIX:
Recent Analyst Action: Jason Zemansky, analyst at Bank of America Securities, reiterates coverage on AlloVir (ALVR) in the Healthcare sector with a Buy rating and a price target of $17 (2 months ago).
TipRanks.com also reports that AlloVir currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $19.50 . The target pricing ranges from a high forecast of $27 down to a low forecast of $15. AlloVir (ALVR)’s last closing price was $1.54 which would put the average price target at 1285.06% upside.Here are 3rd party ratings for ALVR:
Recent Analyst Action: Uy Ear, analyst at Mizuho Securities, reiterates coverage on Arcutis Biotherapeutics (ARQT) in the Healthcare sector with a Hold rating and a price target of $4 (1 week ago).
TipRanks.com also reports that Arcutis Biotherapeutics currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $25.20 . The target pricing ranges from a high forecast of $6 down to a low forecast of $22. Arcutis Biotherapeutics (ARQT)’s last closing price was $2.26 which would put the average price target at 1296.90% upside.Here are 3rd party ratings for ARQT:
To Your Financial Future,
The Editor, WallStreetSectors.com